Booking Holdings Inc vs Gilead Sciences, Inc. — how do they compare? Booking Holdings Inc trades at $210.35 (market cap $159.95B), while Gilead Sciences, Inc. trades at $137.01 (market cap $168.35B). The key difference: Booking Holdings Inc and Gilead Sciences, Inc. are close in size by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| BKNG | GILD | |
|---|---|---|
Market Cap | $159.95B | $168.35B |
Sector | Consumer Cyclical | Health |
52-Week High | $228.83 | $155.80 |
52-Week Low | $154.13 | $110.56 |
Enterprise Value | $163.43B | $191.42B |
Dividend Yield | 0.79% | 2.42% |
Signals from Pluang's Aura AI — not financial advice
Booking Holdings (BKNG) trades at $209.92, down 1.39% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates with $2.54 versus $2.43 expected, and maintains robust profitability with a 25.53% net income margin. Revenue growth continues, reaching $26.92B in 2025, supported by resilient travel demand.
The outlook remains positive with a consensus price target of $239.31, implying 14% upside, though risks include geopolitical volatility and rising debt levels. Analyst sentiment is strongly bullish with 64% buy ratings, while institutional interest is growing, as seen in recent filings. Earnings momentum and free cash flow generation support the investment case, but investors should monitor debt-to-asset trends and competitive pressures.
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Trailing returns across standard periods
Latest headlines on both assets
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →